| 3.7 -0.18 (-4.64%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.13 | 1-year : | 6 |
| Resists | First : | 4.4 | Second : | 5.13 |
| Pivot price | 3.81 |
|||
| Supports | First : | 3.03  |
Second : | 2.19 |
| MAs | MA(5) : | 3.82 |
MA(20) : | 3.73 |
| MA(100) : | 2.57 |
MA(250) : | 2.89 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 54.4 |
| RSI | RSI(14): 59.5 |
|||
| 52-week | High : | 4.55 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LUMO ] has closed above bottom band by 29.1%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.05 - 4.07 | 4.07 - 4.08 |
| Low: | 3.66 - 3.68 | 3.68 - 3.69 |
| Close: | 3.67 - 3.7 | 3.7 - 3.73 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Thu, 05 Sep 2024
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024 - StockTitan
Mon, 19 Aug 2024
Uncovering the Potential of Lumos Pharma Inc (LUMO) Stock - The InvestChronicle
Sun, 04 Aug 2024
Lumos Pharma Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Tue, 23 Jul 2024
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 - StockTitan
Mon, 05 Feb 2024
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth? - Yahoo Finance
Wed, 08 Nov 2023
Lumos stock jumps as phase 2 results bring first oral growth hormone drug closer to market - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 5.32e+006 (%) |
| Held by Institutions | 34.7 (%) |
| Shares Short | 449 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.759e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 603 % |
| Return on Equity (ttm) | -60.5 % |
| Qtrly Rev. Growth | 1.49e+006 % |
| Gross Profit (p.s.) | -20.56 |
| Sales Per Share | -368.23 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.05 |
| Dividend | 0 |
| Forward Dividend | 308330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|